Clinical Trials
3 trialsNCT07098988 2026-05-13
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT07246863 2026-04-21
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT03906071 2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3 Completed